2023
Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I
Unger J, Qian L, Redman M, Tavernier S, Minasian L, Sigal E, Papadimitrakopoulou V, Leblanc M, Cleeland C, Dzingle S, Summers T, Chao H, Madhusudhana S, Villaruz L, Crawford J, Gray J, Kelly K, Gandara D, Bazhenova L, Herbst R, Gettinger S, Moinpour C. Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I. Journal Of The National Cancer Institute 2023, 115: 437-446. PMID: 36625510, PMCID: PMC10086628, DOI: 10.1093/jnci/djad003.Peer-Reviewed Original ResearchConceptsQuality of lifeComposite risk modelAppetite lossSeverity scoreWeek 13Advanced squamous cell lung cancerWeek 7Baseline patient-reported outcomesRandomized phase III trialSquamous cell lung cancerPhase III trialsRisk of progressionShortness of breathCell lung cancerPatient-reported outcomesRisk of deathMultivariable linear regressionEffect of treatmentEvaluable patientsPrimary endpointIII trialsOverall survivalMedian ageAdvanced cancerPrognostic relevance
2019
S1206: A dose-finding study followed by a phase II randomized placebo-controlled trial of chemoradiotherapy (CRT) with or without veliparib in stage III non-small cell lung cancer (NSCLC).
Argiris A, Miao J, Cristea M, Chen A, Sands J, Decker R, Gettinger S, Daly M, Faller B, Albain K, Yanagihara R, Garland L, Byers L, Wang D, Koczywas M, Redman M, Kelly K, Gandara D. S1206: A dose-finding study followed by a phase II randomized placebo-controlled trial of chemoradiotherapy (CRT) with or without veliparib in stage III non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2019, 37: 8523-8523. DOI: 10.1200/jco.2019.37.15_suppl.8523.Peer-Reviewed Original ResearchNon-small cell lung cancerProgression-free survivalStage III non-small cell lung cancerAdverse eventsG3 anemiaG3 thrombocytopeniaOverall survivalUnresectable stage III non-small cell lung cancerPARP inhibitorsG3 adverse eventsG3 oral mucositisG3-4 neutropeniaG4 adverse eventsPhase II dosePlacebo-controlled trialCell lung cancerDose-finding studyPhase I partPhase IIBackbone regimenConsolidation carboplatinEvaluable patientsG3 fatigueG3 nauseaG3 neutropenia
2010
Phase I/II Study of Inhaled Doxorubicin Combined with Platinum-Based Therapy for Advanced Non–Small Cell Lung Cancer
Otterson GA, Villalona-Calero MA, Hicks W, Pan X, Ellerton JA, Gettinger SN, Murren JR. Phase I/II Study of Inhaled Doxorubicin Combined with Platinum-Based Therapy for Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research 2010, 16: 2466-2473. PMID: 20371682, PMCID: PMC4262532, DOI: 10.1158/1078-0432.ccr-09-3015.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdministration, InhalationAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCisplatinDocetaxelDoxorubicinFemaleHumansLung NeoplasmsMaleMaximum Tolerated DoseMiddle AgedSurvival RateTaxoidsTreatment OutcomeConceptsNon-small cell lung cancerCell lung cancerAdvanced non-small cell lung cancerDose-limiting toxicityLung cancerEvaluable patientsPhase I/II studyDose level 1Phase II dosePulmonary function testsDoses of cisplatinStable diseaseII studyProgressive diseaseExpiratory volumePulmonary functionFunction testsVital capacityPulmonary toxicityAdequate organPatientsCancerLevel 1Phase ILevel 2